For research use only. Not for therapeutic Use.
Selective neuronal KCNQ/Kv7 potassium channel opener; an anticonvulsant in development for the potential oral treatment of complex partial seizures and post-herpetic neuralgia (PHN) A water soluble form, Retigabine dihydrochloride (Axon 2252), is available as well.
KEYWORDS: Retigabine | supplier | KCNQ channel opener | D23129 | Ezogabine | Retigabine | D-23129 | CAS [150812-12-7] | Potassium | Kv7.1 | Ion Channel | neuronal | anticonvulsant | seizures | post-herpetic neuralgia | PHN
| Catalog Number | I027192 |
| CAS Number | 150812-12-7 |
| Molecular Formula | C16H18FN3O2 |
| Purity | ≥95% |
| IUPAC Name | ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate |
| InChI | InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21) |
| SMILES | CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N |
| Reference | R Hempel et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab. Disposit. 1999, 27(5), 613-622.
MPG Korsgaard et al. Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of Neuronal Kv7 Channels. J. Pharmacol. Exp. Ther.2005, 314, 282-292. |
